Display options
Cite
Matsumoto T. Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens. Clin Pharmacol. 2014;6:139-48doi: 10.2147/CPAA.S44377.
Matsumoto, T. (2014). Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens. Clinical pharmacology : advances and applications, 6139-48. https://doi.org/10.2147/CPAA.S44377
Matsumoto, Tetsuya. "Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens." Clinical pharmacology : advances and applications vol. 6 (2014): 139-48. doi: https://doi.org/10.2147/CPAA.S44377
Matsumoto T. Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens. Clin Pharmacol. 2014 Sep 26;6:139-48. doi: 10.2147/CPAA.S44377. eCollection 2014. PMID: 25298740; PMCID: PMC4186621.
Copy Download .nbib Format: NLM
Share it on

Clin Pharmacol. 2014 Sep 26;6:139-48. doi: 10.2147/CPAA.S44377. eCollection 2014.

Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens.

Clinical pharmacology : advances and applications

Tetsuya Matsumoto

Affiliations

  1. Department of Microbiology, Tokyo Medical University, Tokyo, Japan.

PMID: 25298740 PMCID: PMC4186621 DOI: 10.2147/CPAA.S44377

Abstract

Arbekacin sulfate (ABK), an aminoglycoside antibiotic, was discovered in 1972 and was derived from dibekacin to stabilize many common aminoglycoside modifying enzymes. ABK shows broad antimicrobial activities against not only Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) but also Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. ABK has been approved as an injectable formulation in Japan since 1990, under the trade name Habekacin, for the treatment of patients with pneumonia and sepsis caused by MRSA. The drug has been used in more than 250,000 patients, and its clinical benefit and safety have been proven over two decades. ABK currently shows promise for the application for the treatment of multidrug-resistant Gram-negative bacterial infections such as multidrug-resistant strains of P. aeruginosa and Acinetobacter baumannii because of its synergistic effect in combination with beta-lactams.

Keywords: Habekacin; MRSA; multidrug-resistant Gram-negative bacteria; synergistic effect

References

  1. J Infect Chemother. 2012 Dec;18(6):816-26 - PubMed
  2. Antimicrob Agents Chemother. 2004 Apr;48(4):1159-67 - PubMed
  3. Antimicrob Agents Chemother. 1989 May;33(5):700-4 - PubMed
  4. Antimicrob Agents Chemother. 1977 Oct;12(4):548-9 - PubMed
  5. Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1663-6 - PubMed
  6. Scand J Infect Dis. 2010 Mar;42(3):231-3 - PubMed
  7. Antimicrob Agents Chemother. 2010 Jul;54(7):3015-7 - PubMed
  8. J Pharmacol Exp Ther. 1986 Feb;236(2):470-5 - PubMed
  9. J Antimicrob Chemother. 1989 Sep;24(3):281-93 - PubMed
  10. J Infect Chemother. 2012 Oct;18(5):609-20 - PubMed
  11. Antimicrob Agents Chemother. 1999 May;43(5):1003-12 - PubMed
  12. Antimicrob Agents Chemother. 1996 Aug;40(8):1785-9 - PubMed
  13. J Infect Chemother. 2014 Jan;20(1):1-5 - PubMed
  14. Drugs Today (Barc). 2003 Apr;39(4):277-85 - PubMed
  15. Eur J Pharm Biopharm. 2006 Aug;64(1):82-91 - PubMed
  16. Jpn J Antibiot. 1988 May;41(5):523-9 - PubMed
  17. Antimicrob Agents Chemother. 2005 Feb;49(2):857-9 - PubMed
  18. Jpn J Infect Dis. 2012;65(1):84-7 - PubMed
  19. Jpn J Antibiot. 2012 Jun;65(3):207-15 - PubMed
  20. Antimicrob Agents Chemother. 1991 May;35(5):837-9 - PubMed
  21. Jpn J Antibiot. 2007 Dec;60(6):344-77 - PubMed
  22. J Infect Chemother. 2012 Apr;18(2):241-6 - PubMed
  23. J Glob Antimicrob Resist. 2013 Jun;1(2):91-96 - PubMed
  24. J Infect Chemother. 2013 Feb;19(1):128-37 - PubMed
  25. Jpn J Antibiot. 1994 Jun;47(6):561-74 - PubMed
  26. Semin Nephrol. 1997 Jan;17(1):27-33 - PubMed
  27. Antimicrob Agents Chemother. 1983 Nov;24(5):797-802 - PubMed
  28. Antimicrob Agents Chemother. 2006 Nov;50(11):3763-9 - PubMed
  29. J Infect Chemother. 2011 Aug;17(4):510-23 - PubMed
  30. Antimicrob Agents Chemother. 1988 Apr;32(4):454-7 - PubMed
  31. Jpn J Antibiot. 2013 Apr;66(2):97-109 - PubMed
  32. Antimicrob Agents Chemother. 2003 Mar;47(3):1010-6 - PubMed
  33. Clin Pharmacol Ther. 1999 Mar;65(3):245-50 - PubMed
  34. Antimicrob Agents Chemother. 1977 Nov;12(5):606-8 - PubMed
  35. Br Med J. 1973 Mar 10;1(5853):569-73 - PubMed
  36. Jpn J Antibiot. 1994 Jun;47(6):676-92 - PubMed
  37. Chest. 1984 Apr;85(4):502-5 - PubMed
  38. J Infect Chemother. 2008 Aug;14(4):279-90 - PubMed
  39. Kansenshogaku Zasshi. 2010 Nov;84(6):727-33 - PubMed
  40. Pediatr Int. 2003 Apr;45(2):175-9 - PubMed
  41. Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2 - PubMed
  42. Jpn J Antibiot. 2001 Jul;54(7):372-81 - PubMed
  43. Infect Chemother. 2013 Mar;45(1):62-8 - PubMed
  44. Clin Pharmacokinet. 1999 Feb;36(2):89-98 - PubMed
  45. J Infect Chemother. 2009 Jun;15(3):156-67 - PubMed
  46. Biochemistry. 1997 Oct 7;36(40):12323-8 - PubMed
  47. J Antimicrob Chemother. 1997 Apr;39(4):471-6 - PubMed

Publication Types